Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | CCR3 | P51677 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19838591 | 0.86 | HTR7 (0.44) | SIGMAR1HTR7HRH1CCR3KCNH2 | |
| Hydrochloric Acid SCHEMBL19839881 | 0.85 | HTR7 (0.43) | SIGMAR1HTR7HRH1CCR3KCNH2 | |
| SCHEMBL19852421 | 0.82 | HTR2A (0.43) | HTR7HRH1CCR3KCNH2 | |
| SCHEMBL19852464 | 0.82 | GPR6 (0.41) | SIGMAR1HTR7HRH1CCR3KCNH2 | |
| SCHEMBL19852013 | 0.82 | SIGMAR1 (0.42) | SIGMAR1HTR7HRH1CCR3KCNH2 | |
| SCHEMBL5207819 | 0.79 | HRH3 (0.74) | HRH3SIGMAR1HRH1CCR3KCNH2 | |
| SCHEMBL19852154 | 0.79 | OPRK1 (0.44) | SIGMAR1HTR7HRH1CCR3KCNH2 | |
| SCHEMBL19852164 | 0.77 | SIGMAR1 (0.44) | SIGMAR1HTR7 | |
| SCHEMBL21072474 | 0.77 | OPRL1 (0.47) | SIGMAR1HTR7KCNH2 | |
| SCHEMBL19852153 | 0.76 | OPRK1 (0.41) | SIGMAR1HTR7HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | HRH3 2732/4885SIGMAR1 612/4885HTR7 112/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | HRH3 2732/4885SIGMAR1 612/4885HTR7 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.